Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROACAROS: Beltavac in HDM Allergic Rhinitis/Rhinoconjunctivitis
NCT05395689Phase 3Recruiting
- Sponsor
- Probelte Pharma
- Start
- Jan 2022
- Primary completion
- Jun 2026
- Modality
- Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC) and house dust mite allergy comparing Beltavac with Placebo (2 arms). Primary endpoint: Combined Nasal Symptom and Medication Score at 12 months. Started Jan 2022; status: recruiting.
02
Drugs
Beltavac
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergy
Beyond the preview
Go deeper on NCT05395689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05395689.